A CVS Health white paper using Aetna claims data finds GLP-1s offset their full cost to plan sponsors only at $350 per month — well below current employer prices of …
A CVS Health white paper using Aetna claims data finds GLP-1s offset their full cost to plan sponsors only at $350 per month — well below current employer prices of …
Novo Nordisk began distributing oral semaglutide 25 mg (Wegovy tablets) in Mexico’s private market on November 11, after COFEPRIS approval in August. The same day, an update to the national …
Costa Rica’s social security fund is running technical studies to choose a GLP-1 molecule for patients with diabetes, with obesity to follow. A diabetes decision is expected in November, as …
Chileans spend nearly US$100 million a year on weight-loss treatment, according to La Tercera, as seven generic semaglutide applications — including Laboratorio Chile’s Selfix — await regulatory review, putting Novo …
Brazil’s Health Ministry has formally asked Conitec to evaluate semaglutide and liraglutide for public-system coverage, opening a process that could reshape the country’s obesity-drug market.
Brazil’s health regulator has approved five new semaglutide injection pens for diabetes treatment, intensifying competition against Novo Nordisk as the molecule’s patent expired in March 2026.
Positive Phase 2b results for elecoglipron and aleniglipron confirm that small-molecule oral GLP-1 receptor agonists can deliver meaningful weight loss without food or fluid restrictions, intensifying competition in obesity and …
You must be logged in to post a comment.